Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2011-12-02 Regulatory Filings
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content includes an announcement about receiving final minutes from a Pre-New Drug Application meeting with the FDA and references an attached press release. The document is relatively short (2570 characters) and primarily serves as a notification of an event rather than a detailed financial or management report. There are no financial statements or detailed analysis included. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into more specific categories like Annual Report or Earnings Release.
2011-12-02 English
MAIN DOCUMENT DESCRIPTION
Director's Dealing
2011-11-21 English
MAIN DOCUMENT DESCRIPTION
Director's Dealing
2011-11-21 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content details the entry into a material definitive agreement involving royalty purchase and financing arrangements with Deerfield Management Company. It includes summaries of multiple agreements and references to exhibits containing the full agreements. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, proxy, or governance document. The document is not an announcement of a report publication but a standalone filing reporting a material event. This fits the category of Capital/Financing Update (CAP), as it concerns financing activities and changes in capital structure through royalty sales and debt restructuring.
2011-11-17 English
FORM 10-Q
Interim / Quarterly Report 9M 2011
2011-11-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, a current report filed with the SEC to announce unscheduled material events or corporate changes. It references a press release attached as Exhibit 99.1 providing initial feedback from a pre-NDA meeting with the FDA. The document is short (2363 characters) and primarily serves as an announcement of an event and the attached press release. It does not contain detailed financial statements, management discussion, or comprehensive report data. According to the rules, such a filing is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements and filings that do not fit other categories.
2011-10-31 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.